EDIGENE Trademark

Trademark Overview

On Tuesday, July 26, 2016, a trademark application was filed for EDIGENE with the United States Patent and Trademark Office. The USPTO has given the EDIGENE trademark a serial number of 87115835. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, January 20, 2020. This trademark is owned by EDIGENE INC.. The EDIGENE trademark is filed in the Pharmaceutical Products category with the following description:

Cells for medical or clinical use; Pharmaceutical preparations for namely, therapeutic pharmaceuticals developed through genome modifications for the treatment of cardiovascular, central nervous system, endocrine, gastrointestinal, genetic immunological, infectious, inflammatory, menopausal, metabolic, autoimmune, musculoskeletal, neurological, ophthalmological, psychiatric, respiratory, urogenital, urological, hematologic and viral diseases and disorders, erectile dysfunction, sexual dysfunction, cancer, pain and diabetes; Pharmaceutical preparations for namely, therapeutic pharmaceuticals developed through genome modifications, namely, antifungal preparations, dermatological preparations, smoking cessation preparations and tissue repair preparations; Diagnostic reagents for medicinal use
edigene

General Information

Serial Number87115835
Word MarkEDIGENE
Filing DateTuesday, July 26, 2016
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, January 20, 2020
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, December 27, 2016

Trademark Statements

Goods and ServicesCells for medical or clinical use; Pharmaceutical preparations for namely, therapeutic pharmaceuticals developed through genome modifications for the treatment of cardiovascular, central nervous system, endocrine, gastrointestinal, genetic immunological, infectious, inflammatory, menopausal, metabolic, autoimmune, musculoskeletal, neurological, ophthalmological, psychiatric, respiratory, urogenital, urological, hematologic and viral diseases and disorders, erectile dysfunction, sexual dysfunction, cancer, pain and diabetes; Pharmaceutical preparations for namely, therapeutic pharmaceuticals developed through genome modifications, namely, antifungal preparations, dermatological preparations, smoking cessation preparations and tissue repair preparations; Diagnostic reagents for medicinal use

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateFriday, July 29, 2016
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameEDIGENE INC.
Party Type21 - New Owner After Publication
Legal Entity Type03 - Corporation
AddressCHANGPING DISTRICT, BEIJING 102206
CN
Party NameNOT AVAILABLE
Party Type20 - Owner at Publication
Legal Entity Type01 - Individual
AddressSan Diego, CA 92129
Party NameNOT AVAILABLE
Party Type10 - Original Applicant
Legal Entity Type01 - Individual
AddressSan Diego, CA 92129

Trademark Events

Event DateEvent Description
Friday, March 13, 2020APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Friday, March 13, 2020TEAS CHANGE OF CORRESPONDENCE RECEIVED
Friday, March 13, 2020TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
Friday, March 13, 2020ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Friday, March 13, 2020TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Friday, March 13, 2020TEAS CHANGE OF OWNER ADDRESS RECEIVED
Tuesday, January 21, 2020ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Monday, January 20, 2020ABANDONMENT - NO USE STATEMENT FILED
Friday, November 22, 2019ASSIGNED TO EXAMINER
Tuesday, May 14, 2019NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, May 10, 2019EXTENSION 4 GRANTED
Friday, May 10, 2019EXTENSION 4 FILED
Friday, May 10, 2019TEAS EXTENSION RECEIVED
Sunday, March 10, 2019TEAS CHANGE OF CORRESPONDENCE RECEIVED
Wednesday, November 28, 2018NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, November 26, 2018EXTENSION 3 GRANTED
Monday, November 26, 2018EXTENSION 3 FILED
Monday, November 26, 2018TEAS EXTENSION RECEIVED
Monday, August 27, 2018TEAS CHANGE OF CORRESPONDENCE RECEIVED
Thursday, May 24, 2018NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, May 22, 2018EXTENSION 2 GRANTED
Tuesday, May 22, 2018EXTENSION 2 FILED
Tuesday, May 22, 2018TEAS EXTENSION RECEIVED
Friday, December 22, 2017NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, December 20, 2017EXTENSION 1 GRANTED
Wednesday, December 20, 2017EXTENSION 1 FILED
Wednesday, December 20, 2017TEAS EXTENSION RECEIVED
Wednesday, June 21, 2017NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Sunday, May 7, 2017EXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED
Wednesday, March 29, 2017ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
Thursday, January 26, 2017EXTENSION OF TIME TO OPPOSE RECEIVED
Tuesday, December 27, 2016OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, December 27, 2016PUBLISHED FOR OPPOSITION
Wednesday, December 7, 2016NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, November 15, 2016APPROVED FOR PUB - PRINCIPAL REGISTER
Monday, November 7, 2016ASSIGNED TO EXAMINER
Friday, July 29, 2016NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Friday, July 29, 2016NEW APPLICATION ENTERED IN TRAM

Related Keywords

edigene preparations namely developed genome dysfunction modifications pharmaceuticals through therapeutic pharmaceutical